CVRx Unveils Positive Real-World Data for Barostim at THT 2026

Event summary

  • CVRx presented late-breaking data from the REBALANCE Registry at THT 2026, showing six-month outcomes in over 400 patients.
  • Multiple scientific presentations highlighted real-world outcomes, cardiac energetics, and LVEF improvements from Barostim therapy.
  • CVRx announced the initiation of the BENEFIT-HF trial, a landmark randomized study supported by CMS Category B IDE coverage.
  • The BENEFIT-HF trial aims to evaluate Barostim in an expanded heart failure population, with enrollment expected to begin in the first half of 2026.

The big picture

CVRx's presentation of positive real-world data at THT 2026 underscores the growing acceptance of Barostim in the heart failure treatment continuum. The initiation of the BENEFIT-HF trial marks a strategic shift toward expanding the therapy's reach, potentially unlocking a larger addressable market. The company's focus on neuromodulation solutions positions it at the forefront of innovative cardiovascular treatments, though execution risks remain.

What we're watching

Clinical Validation
How the REBALANCE Registry data will influence physician adoption and payer coverage for Barostim.
Trial Execution
The pace at which the BENEFIT-HF trial enrolls and delivers results, given its expanded patient population.
Market Expansion
Whether CVRx can sustain momentum in broadening access to Barostim therapy beyond current indications.